Abstract
Introduction
Previous studies have demonstrated that hypertensive patients need concomitant therapy with one or more drugs from different classes of antihypertensive agents to achieve their blood pressure control targets. We performed the first multinational observational study of valsartan/hydrochlorothiazide (HCTZ) single pill combination in Asia to determine the efficacy, safety, and tolerability in hypertensive patients. The objective of this multinational, multicenter, 24-week follow-up observational study is to evaluate the efficacy, safety, and tolerability of valsartan/hydrochlorothiazide single pill combination in the treatment of essential hypertension in the Asia-Pacific region.
Methods
A total of 7567 Asian patients who were diagnosed with stage 1 or stage 2 essential hypertension and who took at least one dose of valsartan/hydrochlorothiazide single pill combination were included in the statistical analyses. A total of 59% were taking antihypertensive medication at the time of the study. Eligible patients received valsartan/hydrochlorothiazide single pill combination 80/12.5 mg tablets orally once daily at visit 1. The investigator could decide the subsequent dose of valsartan/hydrochlorothiazide single pill combination for their patients, and efficacy, safety, and tolerability data were collected at week 4, 12, and 24.
Results
Basal blood pressure was 155.9±13.3 mmHg (systolic) and 96.3±10.1 mmHg (diastolic). Response rates and control rates increased continuously from baseline to the study endpoint at week 24, when they reached 94.6% and 73.2%, respectively. Systolic and diastolic blood pressure reductions were −25.4±15.2 mmHg and −14.9±13.5 mmHg, respectively (P<0.001). Using a four-point global assessment scale, 96.8% of the patients and physicians reported good, very good, or excellent for both their subjective efficacy and tolerability assessments.
Conclusion
In this multicenter, multicountry study including 7567 Asian patients with hypertension, valsartan/hydrochlorothiazide single pill combination was found efficacious, well tolerated, and devoid of any serious adverse effects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Whelton PK, Beevers DG, Sonkodi S. Strategies for improvement of awareness, treatment and control of hypertension: results of a panel discussion. J Hum Hypertens. 2004;18:563–565.
Singh RB, Suh IL, Singh VP, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens. 2000;14:749–763.
Ruilope LM, Burnier M, Muszbek N, et al. Public health value of fixed-dose combinations in hypertension. Blood Press Suppl. 2008;1:5–14.
Volpe M, Tocci G. 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. J Hypertens. 2009;27(Suppl. 3):S3–11.
Mendis S, Abegunde D, Oladapo O, Celletti F, Nordet P. Barriers to management of cardiovascular risk in a low-resource setting using hypertension as an entry point. J Hypertens. 2004;22:59–64.
Dusing R, Handrock R, Klebs S, Tousset E, Vrijeno B. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. J Hypertens. 2009;27:894–901.
Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77:1279–1286.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.
Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother. 2006;7:575–581.
Fanestil DD, Vaughn DA, Ma L, Hyde RH, Printz MP. Thiazide diuretics normalize urinary calcium in spontaneously hypertensive male rats. Kidney Int. 1997;51:1018–1021.
Melby JC. Selected mechanisms of diuretic-induced electrolyte changes. Am J Cardiol. 1986;58:1A–4A.
Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3:72–78.
Black HR, Levy DG, Crikedair N, Rocha R. Predicting age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertension. 2008;2:476–483.
Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PDM, Zhao Y, Grosso A. Efficacy and tolerability of combiation therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 24;8:2303–2311.
Weinberger MH, Glazer RD Crikelair NA, Chiang YT. Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared to monotherapy. J Hum Hypertens. 2010;24:823–830
Pool JL, Glazer R, Crikelair N, Levy D. The role of baseline blood pressure in guiding treatment choice. A secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double blind, placebo-controlled trial. Clin Drug Invest. 2009;29:791–802.
National Heart Lung and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Available at: www.nhlbi.nih.gov/guidelines/hypertension/. Accessed March 14, 2011.
Tiwari H, Kumar A, Kulkarni SK. Prescription monitoring of anti-hypertensive drug utilization at the Panjab University Health Centre in India. Singapore Med J. 2004;45:117–120.
Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006;29:143–151.
Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48;846–852.
Tardif JC, Curnew GP, Leclerc JM, Rehel B. Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4). Can J Clin Pharmacol. 2008;15:e177–e187.
Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:103–112.
Asmar R, Oparil S. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender. Clin Exp Hypertens. 2010;32:499–503.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Lai, WT., Park, JE., Dongre, N. et al. Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. Adv Therapy 28, 427–438 (2011). https://doi.org/10.1007/s12325-011-0014-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0014-4